ASH Clinical News Hematology Pipeline Update: Drug Updates from the | Page 2

Harnessing a revolution in
biology for human health®
Alnylam is developing RNAi therapeutics with an aim to meaningfully impact
patient health. For more information on our clinical programs, including ATTR
amyloidosis, hemophilia and paroxysmal nocturnal hemoglobinuria (PNH),
visit us at www.alnylam.com/patients/alnylam-clinical-trials/

© 2016 Alnylam Pharmaceuticals, Inc.